Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Transcriptomic Landscape of Gallbladder Cancer for Molecular Classification and Tumor Microenvironment Characterization

PROVIDER: PRJDB10737 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR253234_1.fastq.gz	Fastqsanger.gz
	DRR253234_2.fastq.gz	Fastqsanger.gz
	DRR253235_1.fastq.gz	Fastqsanger.gz
	DRR253235_2.fastq.gz	Fastqsanger.gz
	DRR253236_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors

Project description:Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular characteristics. This identification allowed the development of targeted therapies and thus to improve the patient prognosis. This molecular characterization has also revealed the tumor heterogeneity. It may be the cause of treatment resistance and therefore of relapses. Additionally, tumor cells are in constant dialogue with their microenvironment composed of different immune or non immune cells. This microenvironment is now targeted in cancer treatment. To date, there are few studies that combine a deep genomic characterization of both tumor and tumor microenvironment of the patient. Combining the two types of studies on the same tumor should help to define new therapeutic targets and should allow a combination of targeted and immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in colon, kidney and liver cancer).

| 2244099 | ecrin-mdr-crc

Homo sapiens

Project description:Transcriptomic landscape of Gallbladder Cancer (GBC) of 19 samples

| PRJNA1242580 | ENA

Homo sapiens

Project description:Molecular classification of bladder cancer: global mRNA classification versus tumor cell phenotype classification.

| PRJNA326434 | ENA

Homo sapiens

Project description:Molecular Profiling of Gallbladder Cancer (MPOG)

| PRJNA393487 | ENA

Whole exome sequencing of human tumours and cell lines to investigate how ERBB2 and KRAS Alterations mediate response to EGFR inhibitors in early stage Gallbladder Cancer

Project description:Purpose: The uncommonness of gallbladder cancer in the developed world has contributed to the generally poor understanding of the disease. The development of new and effective treatment has been and continues to be a major public health imperative. Methods: We report mutational and copy number analysis of 44 predominantly early-staged gallbladder tumors and 5-gallbladder cancer cell lines by a combination of directed and whole exome sequencing at an average coverage of 100X and above. Using gallbladder cancer cell lines and xenograft mouse models we performed phospho-proteome array profiling, followed by an in-depth functional characterization. Results: We describe recurrent activating ERBB2 somatic mutation in 6 of 44 gallbladder primary tumors with an overall mutation frequency of 13%, along with KRAS activating mutations in 3 of 44 samples. Consistent with whole exome findings, a phospho-proteomic array profile of 49-tyrosine kinase revealed constitutive phosphorylation of ERBB2 and EGFR that were found to heterodimerize. We demonstrate that treatment with ERBB2-specific, EGFR-specific shRNA or with covalent EGFR family inhibitor BIBW-2992 inhibits transformation, survival, migration, invasion, and tumor forming characteristics of gallbladder cancer cells harboring wild type or KRAS (G13D) but not KRAS (G12V) mutation. Furthermore, we show in vivo reduction in tumor size is paralleled by a reduction in the amounts of phospho-ERK in KRAS (G13D) but not in KRAS (G12V) xenografts, validating the in vitro findings Conclusion: Findings from this study implicate ERBB2 as an important therapeutic target in early stage gallbladder cancer. We also present the first evidence that the presence of KRAS (G12V), but not KRAS (G13D) mutation, may preclude gallbladder cancer patients to respond to anti-EGFR treatment, similar to the clinical algorithm commonly practiced to opt for anti-EGFR treatment in colorectal cancer.

2018-12-29 | E-MTAB-6619 | biostudies-arrayexpress

To find out lncRNAs contribute to the development of gallbladder cancer

Project description:To further understand the molecular mechanisms in the development of gallbladder cancer, we employed this microarray to identify lncRNAs associated with gallbladder cancer. 9 pairs of gallbladder cancer tissues and paired normal gallbladder tissues were collected after colecystectomy.

2016-01-08 | E-GEOD-76633 | biostudies-arrayexpress

RNA-Sequencing results of the human Gallbladder cancer (GBC) and adjacent tumor tissues (AT)

Project description:Here we report gene expression profiles of human gallbladder cancer (GC) and adjacent tumor (AT) tissues. This study revealed genes with significant changes in gallbladder cancer tissue, providing a basis for exploring the malignant progression of gallbladder cancer.

2025-06-16 | GSE276931 | GEO

Homo sapiens

Project description:CGCI: HIV+ Tumor Molecular Characterization Project (HTMCP) – Lung Cancer (LC)

| PRJNA172566 | ENA

Homo sapiens

Project description:CGCI: HIV+ Tumor Molecular Characterization Project (HTMCP) – Cervical Cancer (CC)

| PRJNA172569 | ENA

Characterization of cancer-associated fibroblasts from ex vivo germ cell tumors

Project description:Cancer-associated fibroblasts (CAF) as one abundant cell type of the tumor microenvironment are known to have tumor supporting abilities by promoting tumor proliferation and modulating the immunal landscape. In this study, germ cell tumor-derived CAF were molecular and epigenetically characterized to identify CAF secreted signal molecules which play a pivotal role in the GCT-CAF interaction.

2024-11-15 | PXD049249 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data